CagriSema vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Cerebrolysin |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Cerebrolysin:
Detailed Analysis
Commonalities
CagriSema and Cerebrolysin are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Cerebrolysin for Recovery & Healing, Cognitive Performance.
Ready to Learn More?
Looking for trusted sources?